Bosulif (Bosutinib) Patent Expiration, LOE Window & CMS Spending

Bosulif (Bosutinib) by Pfizer: FDA Orange Book core substance LOE 2027-05-23 (last listed 2034-08-28), 2 AB generics, $293.4M 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN203341 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2027-05-23
Last Listed Patent or Exclusivity Date2034-08-28
Orange Book Patents (*PED Extensions)8 patents (4 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$293.4M
2024 Medicare Part D Spend$235.3M
2024 Medicaid Spend$58.0M
Reported Wholesale Price Change (CA SB 17)15 WAC filings (max 24.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.